Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $122.1452W HIGH $186.12
Volume
831.12 K
Value Traded
153.70 M
Short % Float
6.42%
Days to Cover
4.5
+2.58%Week
+3.2%1 Month
-12.24%3 Month
+11.08%6 Month
+64.72%5 Year
+1,205.83%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.88 B
EPS (TTM)
6.94
P/E Ratio
21.09
Ent. Value
14.40 B
Total Shares
101.69 M
Float Shares
100.42 M
Insiders
1.21%
Institutions
102.29%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NBIX Catalyst Timeline
Dated clinical, regulatory and corporate events for Neurocrine Biosciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Neurocrine Biosciences, Inc.
1206Total events
13Upcoming
298Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Poster PresentationValbenazineApprovedPresentation
Poster presentation of EQ-VAS clinically meaningful change analysis from KINECT-PRO and TD-4002 at AMCP Nexus 2026
tardive dyskinesiasource ↗
●Poster PresentationValbenazineApprovedPresentation
Presentation on real-world dosing trends and projections for valbenazine and deutetrabenazine XR in the U.S. at AMCP Nexus 2026
tardive dyskinesiasource ↗
●Poster PresentationPresentation
Presentation on anticholinergic polypharmacy among Medicare beneficiaries with and without tardive dyskinesia at AMCP Nexus 2026
tardive dyskinesiasource ↗
▲Product LaunchPost-Market
VYKAT XR commercially available to U.S. patients
hyperphagia in Prader-Willi syndromesource ↗
●PublicationPresentation
Publication in Orphanet Journal of Rare Diseases on hyperphagia in PWS
Prader-Willi syndrome hyperphagiasource ↗
●Trial InitiationNBI-1117567Trial
Neurocrine initiates Phase 2 study of NBI-1117567 in mild to moderate Alzheimer's disease
mild to moderate Alzheimer's diseasesource ↗
◆Poster PresentationCrinecerfontApprovedPresentation
2-Year CAHtalyst Adult cardiometabolic results for crinecerfont to be presented at Endocrine Nurses Society Annual Symposium 2026
classic congenital adrenal hyperplasiasource ↗
●RWE DataClinical Data
Real-world patient journey mapping data in classic CAH presented at Endocrine Nurses Society Annual Symposium 2026
classic congenital adrenal hyperplasiasource ↗
▲Poster PresentationCrinecerfontApprovedPresentation
2-Year CAHtalyst Pediatric results of crinecerfont presented at Endocrine Nurses Society Annual Symposium 2026
classic congenital adrenal hyperplasiasource ↗
▲IND ClearanceNBI-1117567IND
FDA IND Acceptance for Phase 2 study of NBI-1117567
Alzheimer's cognitionsource ↗
▲Milestone PaymentNBI-1117567Corporate
Nxera to receive US$10 million milestone payment upon IND Acceptance
▲Full ResultsValbenazineApprovedClinical Data
Publication of KINECT-PRO Phase 4 results in CNS Spectrums
tardive dyskinesiasource ↗
▲Trial InitiationNBIP-'1968Trial
Initiation of Phase 1 first-in-human clinical study evaluating NBIP-'1968
obesitysource ↗
▲Full ResultsCRENESSITYApprovedClinical Data
Two-year data from CAHtalyst Adult study announced
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsClinical Data
New VYKAT XR data presented showing durable improvements in hyperphagia
Prader-Willi syndromesource ↗
▲Full ResultsValbenazineApprovedClinical Data
Post-hoc data from KINECT 4 trial announced
tardive dyskinesiasource ↗
●Trial InitiationCrinecerfontApprovedTrial
Phase 2 study initiated in children aged 3 months to under 4 years
classic congenital adrenal hyperplasiasource ↗
▲Quarterly UpdateValbenazineApprovedCorporate
INGREZZA 2026 net sales guidance raised to $2.825-$2.875 billion
tardive dyskinesia and chorea associated with Huntington's diseasesource ↗
●PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
●Trial InitiationCrinecerfontApprovedTrial
Phase 2 study initiated in children aged 3 months to under 4 years
classic congenital adrenal hyperplasiasource ↗
▲Enrollment CompleteCrinecerfontApprovedTrial
Target enrollment achieved for Phase 2 study in EU in children from birth to under 2 years
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsCRENESSITYApprovedClinical Data
Two-year data from CAHtalyst Adult study announced
classic congenital adrenal hyperplasiasource ↗
●PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
▲Full ResultsClinical Data
New VYKAT XR data presented showing durable improvements in hyperphagia and behavioral symptoms
Prader-Willi syndromesource ↗
▲Full ResultsValbenazineApprovedClinical Data
Post-hoc data from KINECT 4 trial announced
tardive dyskinesiasource ↗
▲Late-BreakerPresentation
Late-breaking data at ENDO 2026 showing durable improvements after resuming VYKAT XR following randomized withdrawal
Prader-Willi syndromesource ↗
▲Oral PresentationPresentation
Oral presentation of Study C614 results at ENDO 2026
Prader-Willi syndromesource ↗
▲Poster PresentationPresentation
Poster: VYKAT XR Outcomes Compared to Real-World Data from PATH for PWS Natural History Study (HQ-CT Analysis)
Prader-Willi syndromesource ↗
▲Oral PresentationCRENESSITYApprovedPresentation
First retrospective case series of CRENESSITY in patients with classic CAH due to 11β-hydroxylase deficiency presented at ENDO 2026
classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiencysource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic CAH: Cox Proportional Hazards Analysis (Rapid Fire #ORF32-02 and Poster #MON-495)
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic CAH (Poster #SAT-459)
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Impact of Long-Term Diazoxide Choline Extended-Release Treatment and the Prader-Willi Syndrome Profile Questionnaire
Prader-Willi syndromesource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
Efficacy and Safety of Resuming Diazoxide Choline Extended-Release after 16-Week Randomized Withdrawal in Prader-Willi Syndrome (Study C614)
Prader-Willi syndromesource ↗
◆Poster PresentationCRENESSITYApprovedPresentation
Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric
classic congenital adrenal hyperplasiasource ↗
◆Poster PresentationPresentation
A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia
classic congenital adrenal hyperplasiasource ↗
◆Oral PresentationPresentation
Goldman Sachs 47th Annual Global Healthcare Conference 2026 fireside chat
▲Oral PresentationValbenazineApprovedPresentation
Data presented at AADMD 24th Annual Education Conference showing functional and socio-emotional improvements with INGREZZA in TD patients with intellectual and developmental disabilities
tardive dyskinesiasource ↗
◆Oral PresentationPresentation
William Blair 46th Annual Growth Stock Conference fireside chat
◆Oral PresentationValbenazineApprovedPresentation
Presentation of real-world data on INGREZZA in mild TD at APA 2026
tardive dyskinesiasource ↗
◆Oral PresentationPresentation
Neurocrine Biosciences to present at Bank of America Health Care Conference 2026
▲PublicationCRENESSITYApprovedPresentation
Publication of expert recommendations for glucocorticoid dose reduction after initiating CRENESSITY
classic congenital adrenal hyperplasiasource ↗
Past FDA Catalysts and PDUFA Decisions
How NBIX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-16 | Crinecerfont (CRENESSITY) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
10
Drugs Scored
rNPV / MCap
Top Drug
Top 6%
Mid Cap(rank 40 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| INGREZZA | |||
| CRENESSITY | |||
| VYKAT XR |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Osavampator Small moleculeNCT07196501 | Major Depressive Disorder | Phase 3 | RECRUITING | 550 | Jul 1, 2028 | ||||||
| NBI-1117568 Small moleculeNCT07288320 | Bipolar I Disorder | Phase 2 | RECRUITING | 150 | Feb 1, 2028 | ||||||
| NBI-1117567 Small moleculeNCT07832383 | Alzheimer's Disease | Phase 2 | NOT YET_RECRUITING | 135 | Jun 1, 2028 | ||||||
| NBI-1117570 Small moleculeNCT07288333 | Schizophrenia | Phase 2 | RECRUITING | 120 | Aug 1, 2027 | ||||||
| NBI-1065890 Small moleculeNCT07365462 | Tardive Dyskinesia | Phase 2 | RECRUITING | 100 | Mar 1, 2027 | ||||||
| NBIP-01435 Small moleculeNCT07850739 | Congenital Adrenal Hyperplasia | Phase 2 | NOT YET_RECRUITING | 36 | May 11, 2028 | ||||||
| Crinecerfont Small moleculeMarketedNCT07187375 | Congenital Adrenal Hyperplasia | Phase 3 | ACTIVE NOT_RECRUITING | 312 | Oct 4, 2029 | ||||||
| NBI-1065845 Small moleculeNCT05203341 | Major Depressive Disorder | Phase 3 | COMPLETED | 1,633 | Feb 21, 2024 | ||||||
| NBI-1070770 Small moleculeCompletedNCT06267846 | Major Depressive Disorder | Phase 2 | COMPLETED | 73 | Sep 11, 2025 | ||||||
| NBI-1117568 Small moleculeNCT05545111 | Schizophrenia | Phase 3 | COMPLETED | 1,938 | Jul 10, 2024 | ||||||
| VY-AADC01 Monoclonal antibodyCompletedNCT01973543 | Parkinson's Disease | Phase 1 | COMPLETED | 29 | Jan 24, 2020 | ||||||
| NBI-827104 Small moleculeCompletedNCT04625101 | Epileptic Encephalopathy | Phase 2 | COMPLETED | 24 | Oct 11, 2022 | ||||||
| NBI-827104 Small moleculeCompletedNCT04880616 | Essential Tremor | Phase 2 | COMPLETED | 31 | Jun 8, 2022 | ||||||
| Chronocort Small moleculeCompletedNCT03019614 | Congenital Adrenal Hyperplasia | Phase 3 | COMPLETED | 303 | Apr 1, 2010 | ||||||
| Chronocort Small moleculeCompletedNCT05222152 | Primary Adrenal Insufficiency | Phase 2 | COMPLETED | 58 | Oct 18, 2023 | ||||||
| Valbenazine Small moleculeMarketedNCT05110157 | Schizophrenia | Phase 3 | COMPLETED | 442 | Feb 18, 2025 | ||||||
| Valbenazine Small moleculeMarketedNCT04400331 | Chorea, Huntington | Phase 3 | COMPLETED | 289 | Nov 5, 2025 | ||||||
| NBI-98854 Small moleculeMarketedNCT01393600 | Tardive Dyskinesia | Phase 3 | COMPLETED | 659 | Feb 1, 2012 | ||||||
| Valbenazine Small moleculeMarketedNCT02736955 | Tardive Dyskinesia | Phase 3 | COMPLETED | 161 | Jun 30, 2017 | ||||||
| Valbenazine Small moleculeMarketedNCT05206513 | Dyskinesia | Phase 3 | COMPLETED | 86 | Mar 31, 2026 | ||||||
| Crinecerfont Small moleculeMarketedNCT04045145 | CAH - Congenital Adrenal Hyperplasia | Phase 2 | COMPLETED | 8 | Jul 2, 2021 | ||||||
| NBI-74788 Small moleculeMarketedNCT03525886 | CAH - Congenital Adrenal Hyperplasia | Phase 2 | COMPLETED | 18 | Apr 7, 2020 | ||||||
| NBI-98854 Small moleculeMarketedNCT02256475 | Tourette Syndrome | Phase 2 | COMPLETED | 258 | Dec 1, 2015 | ||||||
| Valbenazine Small moleculeMarketedNCT02879578 | Tourette Syndrome | Phase 2 | COMPLETED | 367 | Nov 1, 2017 | ||||||
| NBI-98854 Small moleculeMarketedNCT01916993 | Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects | Phase 1 | COMPLETED | 24 | Dec 1, 2013 |
Clinical Trial Results
Readouts, endpoints and source filings for every NBIX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| VYKAT XR | Prader-Willi syndrome | Phase 3 | 2026-06-15 | 6.2 points at Year 1; 6.5 points at Year 2; 6.2 points at Year 3; -2.5 in anxiety; -2.4 in rigidity/irritability; -2.3 in compulsivity; -2.1 in aggressive behaviors; -1.5 in disordered thinking; -1.1 in depressionRead More | Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment ...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Boyer David W.Officer (Chief Corp. Affairs Officer) | Sell | -826 8,722 held | $157.45 | 09/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NBIX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RTW INVESTMENTS, LP | 1.8 % (28.6 %) | 213.69 M | 1.27 M | 19.38% ( 205.85 K) |
NBIX Institutional Ownership Trends
NBIX Short Interest
Shares sold short, counted twice a month.
6.42%
Short % of Float
of tradable shares sold short
6.4M
Shares Sold Short
+10.2% vs prior count
4.5 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NBIX ranks across every disease it competes in
Competitive Position is a premium feature
See how NBIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNBIX News
NBIX▲ +0.3%today
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
Neurocrine Biosciences announced a new analysis establishing a 6-point increase on the EQ Visual Analogue Scale as a benchmark for clinically meaningful change in patients with tardive dyskinesia treated with INGREZZA. This finding contextualizes a mean 13.1-point improvement observed in the KINECT-PRO study. The results will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference.
Read more →NBIXNeurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
Neurocrine Biosciences announced a publication in the Orphanet Journal of Rare Diseases, detailing expert insights on hyperphagia in Prader-Willi syndrome (PWS). The manuscript emphasizes the complexity of hyperphagia and the importance of integrated care management. VYKAT XR, an FDA-approved treatment, is noted as a significant advancement in managing this condition.
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
Neurocrine Biosciences has launched a Phase 2 clinical study for NBI-'567, an investigational drug aimed at treating cognitive impairment in adults with mild to moderate Alzheimer's disease. The study will assess the drug's efficacy, safety, and pharmacokinetics over a 12-week period. This initiative reflects Neurocrine's commitment to developing innovative treatments for Alzheimer's and other neurological conditions.
Read more →NBIXNeurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences presented new real-world data on classic congenital adrenal hyperplasia (CAH) at the Endocrine Nurses Society Annual Symposium 2026. The analysis utilized patient records to illustrate the diverse challenges faced by CAH patients throughout their lives. It emphasized the importance of understanding patient experiences to enhance care and support strategies.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Neurocrine Biosciences has announced a conference call and webcast for its third quarter 2026 financial results, scheduled for November 2, 2026. The press release will precede the call, providing financial insights to investors. The company continues to focus on developing treatments for various neurological and psychiatric disorders, showcasing its commitment to patient care.
Read more →NBIXNeurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Neurocrine Biosciences will present research on Prader-Willi syndrome and VYKAT XR at the FPWR 2026 Annual Research Symposium. The studies include the PWS-VISTA observational study, which focuses on real-world evidence of VYKAT XR, and the BRAVE-PWS study, which captures caregiver experiences. The findings aim to deepen understanding of PWS and improve treatment approaches.
Read more →NBIXNeurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
Neurocrine Biosciences has appointed Eiry W. Roberts, M.D., as Chief Medical Officer, effective immediately. Dr. Roberts previously held this role from 2018 to 2025 and has been a Strategic Advisor since. Her return is expected to provide continuity as the company advances its late-stage clinical programs and prepares for significant milestones.
Read more →NBIXNeurocrine Biosciences to Present at Upcoming Investor Conferences in September
Neurocrine Biosciences, Inc. announced its participation in several investor conferences in September 2026. The events include the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference 2026, and Morgan Stanley 24th Annual Global Healthcare Conference. Executives will engage in fireside chats, and webcasts will be available for those unable to attend live.
Read more →NBIXNxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
Neurocrine Biosciences has received IND acceptance from the FDA for NBI-1117567, an investigational drug for Alzheimer's cognition. Nxera Pharma will receive a $10 million milestone payment as part of their collaboration. NBI-1117567 is the third compound from Nxera's muscarinic agonist portfolio to advance to Phase 2, indicating progress in addressing Alzheimer's disease.
Read more →NBIXNeurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
Neurocrine Biosciences announced the publication of KINECT-PRO™ findings, showing that INGREZZA® (valbenazine) significantly improves patient-reported quality of life and functionality in individuals with tardive dyskinesia (TD). The Phase 4 study revealed that 58% of participants achieved symptomatic remission by Week 24, with improvements noted across various severity levels. The results underscore the treatment's effectiveness in enhancing daily functioning and reducing movement severity.
Read more →NBIXNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Neurocrine Biosciences has initiated a Phase 1 clinical study for NBIP-'1968, a triple agonist targeting GLP-1, GIP, and glucagon receptors, aimed at treating obesity. This study will assess the safety and tolerability of the drug in adult participants with varying body mass indices. The development of NBIP-'1968 is part of a broader strategy to expand Neurocrine's obesity treatment options.
Read more →NBIX▼ -10.1%on this news
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
Neurocrine Biosciences reported a strong second-quarter performance for 2026, with total revenues increasing by 39% year-over-year to $959 million. The company raised its net sales guidance for INGREZZA, reflecting robust demand and prescription growth. Additionally, the acquisition of Soleno Therapeutics is expected to strengthen its position in the market. Positive clinical trial results for CRENESSITY further bolster the company's outlook.
Read more →NBIXNeurocrine Biosciences Announces Key Leadership Hiring, Promotions
Neurocrine Biosciences has announced the appointment of three Senior Vice Presidents to enhance its leadership as it enters a new growth phase. Bret Paulson, David Bradfute, and Aaron Vosburgh will take on key roles in market access, intellectual property, and finance, respectively. These changes aim to support the company's expanding commercial portfolio and neuroscience pipeline.
Read more →NBIXNeurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Neurocrine Biosciences has appointed Samir Siddhanti as Chief Business Officer, where he will lead the company's growth strategy and oversee business development. Siddhanti has been with Neurocrine since 2017, playing a key role in strategic partnerships and the recent acquisition of Soleno Therapeutics. His leadership is expected to enhance the company's pipeline and drive future growth.
Read more →NBIXNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Neurocrine Biosciences has announced a conference call and webcast to discuss its second quarter 2026 financial results. Scheduled for July 30, 2026, the call will begin at 1:30 p.m. PT. The company aims to provide updates on its financial performance and ongoing projects, showcasing its commitment to addressing neurological and psychiatric disorders.
Read more →NBIXNeurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences has launched a Phase 2 clinical trial for crinecerfont, targeting children under 4 years with classic congenital adrenal hyperplasia (CAH). The study aims to evaluate the drug's safety and tolerability in a vulnerable population often reliant on high glucocorticoid doses. This initiative reflects the company's commitment to improving treatment options for young patients with CAH.
Read more →NBIXNeurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Neurocrine Biosciences presented a retrospective case series at ENDO 2026, showcasing the effects of CRENESSITY (crinecerfont) in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. The study revealed substantial reductions in adrenal hormone levels and glucocorticoid doses among patients. This case series provides preliminary insights into the treatment of this rare condition, emphasizing the need for further research.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented two-year data on CRENESSITY (crinecerfont) at ENDO 2026, showing positive growth outcomes in pediatric patients with classic congenital adrenal hyperplasia (CAH). The study indicated slowed bone age progression and improved predicted adult height. Caregiver surveys revealed universal satisfaction and optimism regarding the treatment's impact on children's quality of life.
Read more →NBIXNeurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026
Neurocrine Biosciences presented new data from the Phase 3 CAHtalyst Adult study at ENDO 2026, showing that CRENESSITY (crinecerfont) significantly improved cardiometabolic outcomes and reduced glucocorticoid doses in adults with classic congenital adrenal hyperplasia (CAH). Over two years, participants experienced weight loss, improved insulin resistance, and enhanced bone health. Patient surveys indicated high satisfaction and improved quality of life.
Read more →NBIXSoleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
Soleno Therapeutics presented data showing VYKAT XR improved hyperphagia and behavioral symptoms in Prader-Willi syndrome patients after a withdrawal period. Participants who resumed treatment demonstrated durable benefits continuing through two years. The drug also showed sustained improvements compared to natural history data for up to three years. These results reinforce the long-term efficacy of the therapy for this condition.
Read more →About Neurocrine Biosciences, Inc.
Headquarters6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next NBIX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime